Stay updated on Combo Study of SV-BR-1-GM With Retifanlimab Clinical Trial

Sign up to get notified when there's something new on the Combo Study of SV-BR-1-GM With Retifanlimab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Combo Study of SV-BR-1-GM With Retifanlimab Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Observed minor formatting changes on the study page and an updated last-updated timestamp. There are no changes to core study data such as eligibility, endpoints, enrollment, or locations.
    Difference
    0.4%
    Check dated 2025-11-03T01:31:08.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    31 days ago
    Change Detected
    Summary
    Key updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.
    Difference
    2%
    Check dated 2025-10-05T13:23:50.000Z thumbnail image
  4. Check
    38 days ago
    Change Detected
    Summary
    Version bump from v3.0.2 to v3.1.0; no other content changes detected.
    Difference
    0.1%
    Check dated 2025-09-28T09:40:01.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    Updated the page revision from v3.0.1 to v3.0.2 and removed the Back to Top element. No substantive changes to core content, pricing, stock, or other critical information.
    Difference
    0.1%
    Check dated 2025-09-14T00:11:23.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or important information.
    Difference
    0.1%
    Check dated 2025-09-06T20:59:16.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    The web page has added significant drug information related to cyclophosphamide anhydrous and Retifanlimab, along with new topics on breast cancer and various chemical classifications, while removing several specific drug categories and location details.
    Difference
    2%
    Check dated 2025-08-30T15:25:54.000Z thumbnail image

Stay in the know with updates to Combo Study of SV-BR-1-GM With Retifanlimab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Combo Study of SV-BR-1-GM With Retifanlimab Clinical Trial page.